- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: BMS-931699 | BMS931699
Compound class: Antibody
Comment: Lulizumab pegol is a humanised PEGylated anti-CD28 antibody-based biologic, developed as a potential treatment for autoimmune diseases. This so-called domain antibody (dAb) contains the smallest functional binding unit and lacks the divalent structure characteristic of a complete antibody . PEGylation improves solubility and extends circulating half-life .
Peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|A Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE) is underway (June 2015).|
|Mechanism Of Action and Pharmacodynamic Effects|
|CD28 is reported to be involved in the activation T-cells [1,4], which are important drivers of autoimmunity. T cells with no CD28 exhibit impaired T-helper 2 (Th2) responses indicating that CD28 is required for the initiation of the T cell response to antigen . Blockade of CD28 with lulizumab blocks T cell activation, and due to the antibody structure actually drives the T cells in to a state of immune tolerance (anergy) .|